CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug costs.
CVS said that an analysis of its Aetna insurance claims data found that across patients with obesity, diabetes or other conditions, the current prices for GLP-1 drugs add to spending because they are too high to be impacted by lower medical costs.
The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite…
Read the full article at NYPOST.COM
